Abstract
The Gram-positive, mesophilic bacterium Paenibacillus alvei CCM 2051T possesses a two-dimensional crystalline protein surface layer (S-layer) with oblique lattice symmetry composed of a single type of O-glycoprotein species. Herein, we describe a strategy for nanopatterned in vivo cell surface co-display of peptide and glycan epitopes based on this S-layer glycoprotein self-assembly system. The open reading frame of the corresponding structural gene spaA codes for a protein of 983 amino acids, including a signal peptide of 24 amino acids. The mature S-layer protein has a theoretical molecular mass of 105.95 kDa and a calculated pI of 5.83. It contains three S-layer homology domains at the N-terminus that are involved in anchoring of the glycoprotein via a non-classical, pyruvylated secondary cell wall polymer to the peptidoglycan layer of the cell wall. For this polymer, several putative biosynthesis enzymes were identified upstream of the spaA gene. For in vivo cell surface display, the hexahistidine tag and the enhanced green fluorescent protein, respectively, were translationally fused to the C-terminus of SpaA. Immunoblot analysis, immunofluorescence staining, and fluorescence microscopy revealed that the fused epitopes were efficiently expressed and successfully displayed via the S-layer glycoprotein matrix on the surface of P. alvei CCM 2051T cells. In contrast, exclusively non-glycosylated chimeric SpaA proteins were displayed, when the S-layer of the glycosylation-deficient wsfP mutant was used as a display matrix.
Keywords: Cell surface display, S-layer, Nanopatterning, Secondary cell wall polymer biosynthesis, Paenibacillus alvei
1. Introduction
The presentation of heterologous proteins or peptide epitopes on various cell surfaces by genetic engineering has become an intensely used strategy for a wide range of biotechnological applications, including live vaccine development and delivery,1 antibody production,2 peptide library screening,3 whole-cell biocatalysis,4 and bioremediation.5,6 So far, numerous display systems have been studied for both bacteria and yeast.7–12
Outer membrane proteins, lipoproteins, autotransporters, ice nucleation proteins, flagellae, and fimbriae are the most common anchoring motifs of Gram-negative surface display systems, whereas for Gram-positive bacteria, staphylococcal protein A and different S-layer proteins, such as RsaA of Caulobacter crescentus and EA1/Sap of Bacillus anthracis have been utilized.9,13–19 S-Layers, in general, are among the most frequently observed outermost cell surface structures of bacteria. They are composed of individual protein or glycoprotein species, which have the unique feature of self-assembling into a closed two-dimensional crystalline array with nanometer-scaled periodicity. Thus, this matrix is ideally suited for cell surface display approaches, where strict control over position and orientation of functional epitopes or molecules is desired.20 For C. crescentus, the insertion of a protein G IgG-binding domain into certain sites of full length S-layer protein RsaA resulted in functional, immunoreactive surface display at very high density.21 For B. anthracis, targeting of active levansucrase of Bacillus subtilis and immunogenic tetanus toxin fragment C of Clostridium tetani to the cell surface was achieved by translational fusion of the target proteins to the three S-layer homology (SLH) domains of EA1 and Sap, respectively.15,17
Amino- and carboxy-terminal SLH domains of an approximately 55 amino acid-long sequence motif, each, have been identified in several S-layer proteins, in many cell wall-bound exoenzymes, and in outer membrane proteins.22 Although the overall sequence similarity of SLH domains is rather low, a highly conserved TRAE motif has been identified to play a key role for the binding function of SLH domains.23 In the case of S-layer (glyco)proteins, it has been shown that these anchoring modules do not directly bind to peptidoglycan, but to a non-classical secondary cell wall polymer (SCWP)24–28 carrying either pyruvate or carboxyl group-containing modifications. In B. anthracis and Thermus thermophilus, pyruvylation of SCWPs was shown to be dependent on the presence and activity of the polysaccharide pyruvyltransferase CsaB.24,26 Further, in different Bacillus strains, a perfect correlation between the occurrence of CsaB homologues and the presence of SLH domains exists, leading to the conclusion that the interaction between pyruvylated SCWP and SLH domains is widespread in bacteria and has been conserved during evolution.24,26
In the present study, we lay the groundwork for the development of a peptide/protein and glycan cell surface co-display system based on the glycosylated S-layer protein SpaA of Paenibacillus alvei CCM 2051T. This is a very timely approach, since, due to the complexity of their biosynthesis, glycans have escaped cell surface display approaches, so far. P. alvei CCM 2051T is a mesophilic, Gram-positive bacterium that is covered with an oblique S-layer nanolattice. The S-layer proteins are naturally O-glycosylated, exposing long-chain saccharides with the structure [→3)-β-d-Galp-(1[α-d-Glcp-(1→6)]→4)-β-d-ManpNAc-(1→]n~23-[GroA-2→OPO2→4-β-d-ManpNAc-(1→4)]-[3)-α-l-Rhap-(1→]n = 3 3)-β-d-Galp-(1→O)-Tyr to the environment.29 This glyco-nanolattice is anchored to the bacterial cell wall via a pyruvate-containing SCWP with the structure [(Pyr4,6)-β-d-ManpNAc-(1→4)-β-d-GlcpNAc-(1→3)]n~11-(Pyr4,6)-β-d-ManpNAc-(1→4)-α-d-GlcpNAc-(1→. These pyruvate-containing and, hence, overall anionic glycan chains are linked via phosphate-containing groups to muramic acid residues of the peptidoglycan layer.30
We describe herein (i) the identification of the spaA gene coding for the S-layer protein of P. alvei CCM 2051T, (ii) its utilization as an in vivo surface co-display system, and (iii) the identification of several open reading frames in the upstream region of spaA coding for enzymes putatively involved in the biosynthesis of the native cell wall anchor of the S-layer nanolattice, which is the pyruvylated SCWP.
For proof of concept, full-length SpaA was expressed with a carboxy-terminal hexahistidine tag and with enhanced green fluorescent protein as a fusion partner, respectively. Either chimeric protein was shown to be displayed on the cell surface and glycosylated by the native glycosylation machinery of P. alvei CCM 20151T. To our knowledge, this is the first report on the co-display of a fused functional epitope and an O-glycosidically linked glycan on a bacterial cell surface in a nanolattice-like fashion. This strategy is opening up new avenues for controlled high-density co-display of protein- and carbohydrate-mediated biological functions with defined orientation and with nanometer-scaled precision. This approach ideally mimics, especially for the glycan-mediated functions, the naturally occurring clustering effect. When the S-layer glycosylation-deficient wsfP mutant was used for cell surface display, exclusively non-glycosylated chimeric SpaA proteins were obtained.31
2. Results
2.1. General description of the organism
The cell surface of the type culture strain P. alvei CCM 2051T (ATCC 6344; DSM 29) is completely covered with an oblique S-layer lattice composed of identical O-glycoprotein species. Various aspects of its crystalline S-layer including ultrastructural characterization,32,33 glycosylation analysis,29,33 and glycan biosynthesis34 have been investigated in the past. In SDS–PAGE, the S-layer glycoprotein is separated into three bands with apparent molecular masses of approximately 105, 160, and 240 kDa, respectively. The two high molecular mass bands give a positive PAS staining reaction, corresponding to mono- and di-glycosylated S-layer proteins.31
2.2. Isolation and molecular characterization of spaA
After chemical deglycosylation of the S-layer glycoprotein, Edman degradation revealed the N-terminus of the mature protein to have the amino acid sequence ADAAKTTQEK. Based on this information, the degenerate oligonucleotide primer proof_wSpa_-for was designed by in silico reverse translation. Identification of the entire spaA gene was accomplished using a gene walking approach, starting with the primer specific for the N-terminus of spaA. The sequence was deposited at GenBank under the accession number FJ751775. The spaA gene revealed one ORF extending 2952 nt, encoding a putative protein of 983 amino acids with a calculated molecular mass of 108.55 kDa. The ORF starts with an ATG at nucleotide position 1, preceded by a typical ribosomal binding site (Shine–Delgarno sequence) 19 nt upstream of the start codon and a putative promoter region comprising a −10 sequence (TTGTATAAT) located 232 nt upstream of the translation start and a putative −35 sequence (TTTACG) starting 252 nt in front of the start codon. 7 nt downstream of the TAA stop codon, a putative ρ-independent transcriptional termination signal was identified. The terminator consists of a palindromic stem loop sequence of 39 nt with a perfect stem of 13 nt. The average G+C content of the whole spaA gene was calculated to be 38.6%.
2.3. Description of the S-layer protein SpaA
The amino acid sequence ADAAKTTQEK obtained by amino-terminal sequencing of chemically deglycosylated, mature SpaA was identified at positions 25–34 of the spaA gene product, indicating that the first 24 amino acids of SpaA constitute a signal sequence, which is cleaved at the Gly-Ala motif during biosynthetic protein processing. The overall amino acid composition of mature SpaA is within the typical data reported for S-layer proteins of Gram-positive bacteria,35 exhibiting a high content of hydrophobic and acidic amino acids and lacking cysteine. Mature SpaA has a calculated theoretical molecular mass of 105.95 kDa and a pI of 5.83. A conserved motif search revealed the presence of three SLH domains (PF00395) at the amino-terminal region of the S-layer protein; these comprise the amino acid stretches aa 25–65, aa 82–129, and aa 140–181, respectively (Table 1). The comparison of the three SLH domains with the SLH domain profile is depicted in Figure 1.
Table 1.
Predicted gene products encoded by the SCWP biosynthesis locus of P. alvei CCM 2051T and S-layer protein structural gene spaA together with database homologies
| ORF | orf1 | |||
| Length/mol. mass | 657/73.18 | |||
| Signal peptide 1–23 |
|
|||
| DUF916 (PF06030) 1–30 | ||||
| Conserved motifs and regions | DUF204 (PF02659) 341–395 | |||
| DUF808 (PF05661) 460–641 | ||||
| DUF981 (PF06168) 521–558 | ||||
| DUF2061 (PF09834) 608–650 | ||||
| Related proteins | Name/putative function | Organism | Identity/similarity (%) | Accession No. |
| Hypothetical protein GYMC10DRAFT_1551 | Geobacillus sp. Y412MC10 | 52/72 | ZP_03037718 | |
| Hypothetical protein Pjdr2DRAFT_3486 | Paenibacillus sp. JDR-2 | 48/66 | ZP_02848379 | |
| ORF | csaB | |||
| Length/mol. mass | 396/43.59 | |||
| Conserved motifs and regions | PS_pyruv_trans (PF04230) 7–357 |
|
||
| Related proteins | Name/putative function | Organism | Identity/similarity (%) | Accession No. |
| Polysaccharide pyruvyl transferase | Geobacillus sp. Y412MC10 | 49/64 | ZP_03037717 | |
| CsaB protein | Bacillus anthracis strain Ames | 37/56 | NP_843396 | |
| ORF | tagA | |||
| Length/mol. mass | 252/28.69 | |||
| Conserved motifs and regions | Glyco_tran_WecB (PF03808) 60–231 |
|
||
| Related proteins | Name/putative function | Organism | Identity/similarity (%) | Accession No. |
| Glycosyl transferase, WecB/TagA/CpsF family | Paenibacillus sp. JDR-2 | 62/79 | ZP_02848377 | |
| N-Acetylglucosaminyldiphosphoundecaprenol N-acetyl-β-d-mannosaminyltransferase | Bacillus cereus ATCC 14579 | 45/65 | NP_835080 | |
| ORF | tagO | |||
| Length/mol. mass | 377/40.47 | |||
| Signal peptide 1–33 |
|
|||
| Glycos_transf_4 (PF00953) 84–247 | ||||
| Conserved motifs and regions | ||||
| Related proteins | Name/putative function | Organism | Identity/similarity (%) | Accession No. |
| TagO protein | Bacillus megaterium DSM319 | 53/72 | CAL44583 | |
| Undecaprenyl-phosphate N-acetylglucosaminyl 1-phosphate transferase | Lysinibacillus sphaericus C3–41 | 52/72 | YP_001696879 | |
| ORF | slhA | |||
| Length/mol. mass | 1335/148.46 | |||
| Signal peptide 1–31 | ||||
| Galactose-binding domain-like (CBM6) 91–200 |
|
|||
| Conserved motifs and regions | Big_3 (PF07523) 493–513 | |||
| SLH (PF00395) 1125–1169 | ||||
| SLH (PF00395) 1198–1242 | ||||
| SLH (PF00395) 1267–1319 | ||||
| Related proteins | Name/putative function | Organism | Identity/similarity (%) | Accession No. |
| S-layer domain protein | Paenibacillus sp. JDR-2 | 49/63 | ZP_02848374 | |
| Hypothetical protein BBR47_54190 | Brevibacillus brevis NBRC 100599 | 46/61 | YP_002774900 | |
| ORF | spaA | |||
| Length/mol. mass | 983/108.55 | |||
| Signal peptide 1–24 |
|
|||
| SLH (PF00395) 25–65 | ||||
| Conserved motifs and regions | SLH (PF00395) 82–129 | |||
| SLH (PF00395) 140–181 | ||||
| Related proteins | Name/putative function | Organism | Identity/similarity (%) | AccessionNo. |
| S-layer domain protein | Geobacillus sp. Y412MC10 | 43/59 | YP_003245899 | |
| S-layer domain-containing protein | Paenibacillus sp. oral taxon 786 str. D14 | 43/59 | ZP_04851624 | |
| ORF | orf7 | |||
| Length/mol. mass | 468/52.58 | |||
| Conserved motifs and regions |
|
|||
| Signal peptide 1–20 | ||||
| Related proteins | Name/putative function | Organism | Identity/similarity (%) | Accession No. |
| Hypothetical protein GYMC10DRAFT_0729 | Geobacillus sp. Y412MC10 | 24/44 | ZP_03036896 | |
| Hypothetical protein Pjdr2DRAFT_3479 | Paenibacillus sp. JDR-2 | 24/44 | ZP_02848309 | |
Figure 1.

Comparison of the three SLH domains of SpaA with the S-layer homology (SLH) domain profile (PROSITE No.: PS51272). The amino-terminal region starting with the first amino acid of the mature protein (aa 25) is aligned with the PROSITE sequence logo. The total height of an amino acid position depends on the degree of conservation in the corresponding multiple sequence alignment and the height of each letter is proportional to the observed frequency of the particular amino acid.
A homology search using the BLASTP program showed that the amino acid sequence of SpaA shows moderate identities with other surface exposed proteins of different Bacillaceae. A phylogenetic tree was constructed by pairwise alignment of SpaA with the first 100 proteins of this BLAST search (Fig. 2). The rooted tree shows that SpaA is closely related to S-layer domain proteins of Paenibacillus sp. JDR-2 and Geobacillus sp. Y412MC10 as well as to an S-layer domain-containing protein of Paenibacillus sp. oral taxon 786 strain D14. A rather distant relationship could be observed between SpaA and several cell surface proteins of different clostridia. The global identity and similarity values of SpaA compared with other well-characterized S-layer proteins are summarized in Table 2. Considering these data, it is obvious that regions of high homology are neither present in the N-termini, responsible for binding of the S-layer protein to the cell wall, nor in the residual amino acid sequence. This corroborates the general concept of low primary sequence similarity of S-layer proteins, even of those of phylogenetically closely related bacteria.36
Figure 2.
Phylogenetic tree of the S-layer protein SpaA of P. alvei CCM 2051T and its closest relatives. The calculation was done with the Blast Tree View Widget using the Neighbor Joining method.
Table 2.
Amino acid sequence comparison between SpaA and different well-characterized S-layer proteins using the EMBOSS Pairwise Alignment Algorithms (Global alignment method, Blosum62 matrix)
| Protein | Organism | Accession no. | SLH domains | Analyzed region | Identity% | Similarity% |
|---|---|---|---|---|---|---|
| SbpA | Lysinibacillus sphaericus CCM 2177 | AAF22978 | 33–76 92–135 152–199 |
1–1268 1–200 |
18.8 26.6 |
29.1 38.3 |
| Surface layer protein | Lysinibacillus sphaericus 2362 | AAA50256 | 32–76 92–135 152–199 |
1–1176 1–200 |
26.5 26.7 |
39.3 38.5 |
| SlpC | Lysinibacillus sphaericus C3–41 | ABQ00414 | 32–76 92–135 152–199 |
1–1176 1–200 |
26.5 26.7 |
39.3 38.5 |
| Sap | Bacillus anthracis strain sterne | YP_027117 | 33–76 94–135 155–197 |
1–814 1–200 |
22.2 22.6 |
34.8 36.7 |
| EA1 | Bacillus anthracis strain sterne | YP_027118 | 33–76 94–136 156–197 |
1–862 1–200 |
21.8 23.1 |
36.1 39.1 |
| CTC protein | Bacillus thuringiensis CTC ssp. finitimus | CAA09981 | 33–76 94–135 155–198 |
1–816 1–200 |
20.7 22.6 |
34.0 37.4 |
| SlpA | Bacillus thuringiensisNRRL 4045 ssp. galleriae | CAB63252 | 33–76 94–136 156–197 |
1–821 1–200 |
22.2 24.4 |
35.3 36.4 |
| SbsB | Geobacillus stearothermophilus PV72 p2 | CAA66724 | 33–76 92–133 150–191 |
1–920 1–200 |
21.8 21.0 |
36.1 36.1 |
| Middle wall protein precursor | Brevibacillus brevis 47 | AAA22760 | 32–72 93–136 — |
1–1053 1–200 |
20.3 27.1 |
31.8 44.9 |
| S-Layer protein precursor | Thermoanaerobacter kivui | AAA21930 | 30–73 95–137 — |
1–762 1–200 |
19.2 27.4 |
29.5 38.4 |
| P100 protein | Thermus thermophilus HB8 | CAA40609 | 24–67 — — |
1–917 1–200 |
21.1 27.2 |
34.2 45.6 |
| SlpA | Clostridium thermocellum NCIB 10682 | AAC33404 | — 94–134 — |
1–1036 1–200 |
23.7 18.6 |
40.4 29.6 |
For analysis of full length proteins, SpaA from aa 1 to 983 was used and for comparison of the amino-terminal parts aa 1–200 were included.
2.4. Description of the SCWP biosynthesis locus
Upstream and downstream of the spaA gene, several genes were identified, which are most likely involved in the SCWP biosynthesis of P. alvei CCM 2051T (Fig. 3). By in silico analysis using the Escherichia coli σ70 promoter consensus sequence, putative promoter sites located upstream of orf1, tagO, slhA, spaA, and orf7 were recognized. In addition to the ρ-independent bacterial terminator downstream of spaA, a single terminator was identified downstream of the slhA gene. The prediction of transcription units for the complete ~14-kb DNA fragment resulted in a polycistronic RNA containing orf1, csaB, and tagA in addition to four separate monocistronic RNAs for tagO, slhA, spaA, and orf7. The putative gene products of the SCWP biosynthesis locus have been analyzed by extensive database comparison and are discussed in the order of their appearance within the analyzed region.
Figure 3.
Genetic organization of the SCWP biosynthesis locus of P. alvei CCM 2051T. Predicted open reading frames are indicated by horizontal arrows with the respective gene designations indicated above the arrow. Genes encoding similar functions in SCWP biosynthesis have a similar gray scaling code. Genes coding for proteins with unknown function are indicated in black. Genes highlighted in gray encode putative glycosyltransferases. White indicates the csaB gene encoding the pyruvyltransferase. The structural gene spaA is highlighted in lightest gray. Putative promoters and terminators are represented as flags and hairpins, respectively. Monocistronic and polycistronic mRNAs are depicted as vertical black arrows. The graphic representation of the G+C percentages is given below the locus map.
2.4.1. orf1
The gene product of orf1 contains eight potential transmembrane domains at its carboxy-terminal part and several domains of unknown functions (DUFs) also found in putative bacterial cell surface and hypothetical transmembrane proteins. The signal peptide of 23 amino acids is followed by a 340 amino acid-containing loop potentially facing the cell exterior. The Conserved Domain Finder (National Center for Biotechnology Information) found a weak similarity to the sublancin ABC transporter SunT of B. subtilis 168, suggesting that this protein might act as an exporter37 like CsaA in the biosynthesis of other pyruvylated SCWPs.24,26
2.4.2. csaB
Throughout the whole gene csaB is highly homologous to genes coding for pyruvyltransferases (CsaB) in various Bacillus strains, with the translation product containing a polysaccharide pyruvyltransferase domain. In B. anthracis and T. thermophilus, CsaB is involved in the addition of pyruvyl groups to the SCWP, a frequently necessary reaction for anchoring of cell wall associated proteins containing SLH domains.24–27 The presence of a pyruvate-containing SCWP in P. alvei CCM 2051T suggests that CsaB is responsible for SCWP-pyruvylation in this organism.30
2.4.3. tagA and tagO
The deduced 252- and 377-amino acid proteins encoded by tagA and tagO reveal high similarity to the glycosyltransferases TagA and TagO of different Bacillaceae, respectively. In B. subtilis, both enzymes are involved in the biosynthesis of teichoic acids, where TagO couples N-acetylglucosamine (GlcNAc) to the membrane-embedded lipid undecaprenylpyrophosphate and TagA catalyzes the addition of N-acetylmannosamine (ManNAc) to produce the lipid-linked GlcNAc-ManNAc disaccharide.38,39 Since a ManNAc-Glc-NAc backbone disaccharide motif is found in the SCWP of P. alvei CCM 2051T, it is conceivable that both enzymes are involved in the biosynthesis of this cell wall polysaccharide.29,38
2.4.4. slhA
The slhA gene product contains three carboxy-terminal SLH domains and is similar to SLH domain-containing proteins of various Gram-positive bacteria. In the central part of the putative protein, a bacterial Ig-like domain found in a variety of bacterial surface proteins is identified.40 A galactose-binding domain (CBM6) typical for proteins binding to specific ligands, such as cell-surface-attached carbohydrate substrates, was detected in the amino-terminal part. This observation leads to the suggestion that SlhA might be a cell surface-anchored exoenzyme or a receptor.
2.4.5. orf7
No homology was found for this incomplete ORF or its putative protein product.
2.5. Expression and display of chimeric SpaA constructs on the cell surface
The expression of the hexahistidine tagged S-layer protein SpaA_6HIS and the chimeric fusion protein SpaA_EGFP in P. alvei CCM 2051T wild-type and in wsfP::Ll.LtrB mutant cells, respectively, was performed constitutively from the vector pEXALV and confirmed by immunoblot analysis of whole-cell lysates using anti-His-tag and anti-GFP antibody, respectively (Fig. 4A and B). In either case, three bands, most possibly corresponding to the non-glycosylated, mono-glycosylated, and di-glycosylated forms31 of SpaA_6HIS and SpaA_EGFP were detected when P. alvei CCM 2051T carrying either pEXALV_SP_SpaA_6HIS or pEXALV_SP_SpaA_EGFP, respectively, was used as an expression host, while no such proteins were detected with P. alvei CCM 2051T carrying the parental plasmid pEXALV (data not shown). Since the transfer of the completed glycan chain to the S-layer protein is predicted to occur either co-secretionally or on the external face of the cytoplasmic membrane,41 these results indicate that SpaA_6HIS and SpaA_EGFP are correctly expressed and targeted to the cell surface of P. alvei CCM 2051T. For P. alvei CCM 2051T wsfP::Ll.LtrB mutant cells, which are, due to the deletion in the initiation enzyme of S-layer glycan biosynthesis, of a glycan-deficient phenotype, only a single band corresponding to non-glycosylated SpaA_6HIS and SpaA_EGFP was detected (Fig. 4). Semi-quantitation of the amount of produced recombinant S-layer fusion proteins was performed from Western blots developed with fluorescence-labeled antibodies using the Li-Cor Odyssey Application software. Comparing the expression levels of the recombinant non-glycosylated chimera from P. alvei CCM 2051T wsfP::Ll.LtrB mutant cells with that of the corresponding chimera produced in glycosylation-competent P. alvei CCM 2051T cells revealed equal amounts of S-layer fusion proteins, regardless of the glycosylation status. This was inferred from the combined intensities of the non-, mono-, and di-glycosylated bands (Fig. 4A and B, lane 1) being identical to that of the single band originating from the glycosylation-deficient mutant (Fig. 4A and B, lane 2). This indicates that the developed system is well suited for peptide/protein and glycan co-display.
Figure 4.
Western blot with fluorescence detection of chimeric S-layer proteins. (A) SpaA_6HIS detected using an anti-His-tag antibody in combination with goat anti-mouse IgG IR Dye 800CW conjugate. (B) Detection of SpaA_EGFP using an antibody raised against GFP in combination with goat anti-mouse IgG IR Dye 800CW conjugate. The constructs were analyzed by SDS–PAGE (8% gel) and transferred to a PVDF membrane followed by immunoblot detection. Tri-banded appearance corresponds to non-glycosylated (N), mono-glycosylated (M), and di-glycosylated (D)31 chimeric SpaA proteins produced by P. alvei CCM 2051T wild-type cells (lanes 1). For P. alvei CCM 2051T wsfP::Ll.LtrB mutant cells, sole bands corresponding to non-glycosylated SpaA chimera were detected (lanes 2). Two milligrams of intact cells were loaded per well.
To confirm the surface localization of the chimeric S-layer proteins, immunofluorescence microscopy was used (Fig. 5). For SpaA_6HIS, P. alvei CCM 2051T wild-type cells were probed and fluorescently stained with the penta-His Alexa Fluor 555 conjugate. Cells harboring pEXALV_SP_SpaA_6HIS were brightly fluorescent, indicating that SpaA_6HIS was successfully displayed on the surface (Fig. 5C). Surface display of SpaA_EGFP was confirmed by direct fluorescence microscopy (Fig. 5D). P. alvei CCM 2051T wild-type and wsfP::Ll.LtrB mutant cells (not shown) showed identical results in immunofluorescence microscopy, whereas cells carrying the parental plasmid pEXALV were not stained at all (Fig. 5A and B).
Figure 5.
Immunofluorescence microscopy of P. alvei CCM 2051T wild-type cells displaying chimeric S-layer glycoproteins. (A and B) Control P. alvei CCM 2051T wild-type cells harboring pEXALV. Recombinant P. alvei CCM 2051T wild-type cells harboring (C) pEXALV_SP_SpaA_6HIS, and (D) pEXALV_SP_SpaA_EGFP. For immunofluorescence staining of surface-located SpaA_6HIS, cells were probed with the penta-His Alexa Fluor 555 Conjugate (Qiagen). The TRITC and the GFP LP filter blocks were used for detection of Alexa Fluor 555 (A and C) and EGFP (B and D), respectively. Corresponding brightfield images of the same cells are shown in the left. The immunofluorescence images of the wsfP::Ll.LtrB mutant strain are identical to those observed for wild-type cells and hence not shown.
These results show the proper and efficient display of SpaA_6-HIS and SpaA_EGFP on the cell surface of P. alvei CCM 2051T simultaneously with the native S-layer glycans while maintaining the S-layer inherent feature of a dynamically closed two-dimensional nanolattice covering the entire bacterium.
3. Discussion
Monomolecular isoporous S-layers cover many bacterial cells in the form of nanolattices, that is, two-dimensional crystalline arrays with nanometer-scale periodicity. An intact closed S-layer nanolattice on an average-sized, rod-shaped bacterium consists of ~500,000 monomers making it ideally suited for highly efficient display of a significant number of functional epitopes in defined and precise orientation.42
In this report, we describe the identification of the structural gene encoding the S-layer protein SpaA of P. alvei CCM 2051T and the development of an in vivo surface co-display system using this protein as a cell wall anchor. This was exemplified by the presentation of a heterologous peptide epitope and a functional protein, respectively, in addition to the native S-layer glycan chain (Fig. 6). The strategy is based on the continuous expression of plasmid-encoded S-layer chimera in P. alvei CCM 2051T using a constitutive promoter and its export, glycosylation as well as surface anchoring, in competition with the wild-type S-layer glycoprotein.
Figure 6.
Strategy for in vivo cell surface co-display of functional epitopes on P. alvei CCM 2051T cells. Schematic picture showing the cell wall profile with the peptide/protein epitope and the glycans being presented in nanopatterned fashion to the exterior of the bacterial cell. Non-glycosylated (N), mono-glycosylated (M), and di-glycosylated (D)31 chimeric SpaA proteins are distributed equally over the cell surface.
For proof of concept, the hexahistidine tagged S-layer protein SpaA_6HIS as well as the chimeric fusion protein SpaA_EGFP was constructed and their cell surface localization was demonstrated by immunofluorescence staining and fluorescence microscopy. The used P. alvei CCM 2051T surface display vector pEXALV_SP_SpaA can be generally utilized for translational fusion of various functional epitopes to the C-terminus of SpaA, their subsequent export and surface presentation. By immunoblot analysis, for both surface-displayed constructs—SpaA_6HIS and SpaA_EGFP—a non-glycosylated, mono-glycosylated, and di-glycosylated form resulting from the native S-layer protein O-glycosylation system of wild-type P. alvei CCM 2051T was detected, which reflects the native SpaA O-glycosylation pattern. This indicates the suitability of this system for the future in vivo cell surface co-display of engineered, bioactive glycan structures based on the native S-layer glycans, in addition to peptide/protein epitopes. Since the ongoing investigation of the S-layer glycosylation machinery of P. alvei CCM 2051T revealed some promising insights,41 this bacterium is a prime candidate for the design and presentation of S-layer neoglycoproteins by means of genetic carbohydrate engineering.43 Thereby, the S-layer glycosylation deficient mutant strain wsfP::Ll.LtrB, carrying an insertion in the wsfP gene coding for the initiation enzyme of S-layer glycan biosynthesis, provides the possibility of turning on the functional glycosylation of any SpaA chimera, when the activity of WsfP is reconstituted by plasmid-based expression of wsfP.31
Besides the attachment of a tailor-made, functionalized S-layer protein to the cell envelope, secretion into the medium can also be a desired option for specific purposes, avoiding time- and cost-consuming purification steps. In this context, the anchoring mechanism of the S-layer protein was investigated, starting with the observation of three SLH domains located at the N-terminus of SpaA. The typical, highly conserved TRAE motif could be identified in the first SLH domain (aa 25–65) of SpaA. In the second (aa 82–129) and third (aa 140–181) SLH domain, two different variants of this motif, TVEE and TRAQ, are present. However, these motif variants have also been reported to be functional.23 Since these SLH domains are known to play a key role in mediating the cell wall binding of various proteins by interacting with SCWPs carrying pyruvate modifications, it was not surprising to identify a pyruvyltransferase encoding gene in the upstream region of spaA. Furthermore, with tagA and tagO, both coding for glycosyltransferases, two additional enzymes obviously involved in SCWP biosynthesis of P. alvei CCM 2051T were identified. Due to the similarity of TagO to an undecaprenylphosphate N-acetylglucosaminyl-1-phosphate transferase, it can be assumed that TagO attaches GlcNAc to the membrane-embedded lipid carrier undecaprenylpyrophosphate at the cytoplasmic side of the membrane. The next step in the biosynthesis pathway would be the addition of ManNAc catalyzed by the N-acetylglucosaminyl diphosphoundecaprenol N-acetyl-β-d-mannosaminyltransferase TagA, to produce the lipid-linked GlcNAc-ManNAc disaccharide. The transfer of the pyruvate modification to ManNAc residue is accomplished by the pyruvyltransferase CsaB. Additional enzymes required for the export and for the formation of the covalent linkage between SCWP and peptidoglycan could not be identified, so far. The prediction of transcription units for the SCWP biosynthesis locus showed that orf1, csaB, and tagA are located on a polycistronic mRNA. This finding is supported by the closed spacing and the absence of a promoter consensus sequence between these three genes. The role of the gene product of orf1 being part of this polycistronic mRNA remains, due to the lack of reliable sequence similarities, speculative and needs to be further investigated. The encoded protein could be possibly involved in the export of the pyruvylated polymer. TagO, slhA, and spaA are predicted to be transcribed monocistronically. The presence of three SLH domains located at the C-terminus of SlhA argues for its surface exposure and turns this protein into an eligible candidate for co-display of chimeric SpaA- and SlhA proteins interacting with each other or binding a target molecule in two different manners.
In conclusion, we have demonstrated the in vivo cell surface co-display of a heterologous peptide epitope and a functional protein fused to the N-terminus of the S-layer glycoprotein SpaA of P. alvei CCM 2051T in addition to the S-layer glycans. The developed strategy is the starting point for the future in vivo presentation of different peptides and proteins combined with bioactive glycans, which may have great value in the fields of receptor mimics, vaccine development, or drug delivery.
4. Experimental
4.1. Bacterial strains and growth conditions
P. alvei CCM 2051T (Table 3) was obtained from the Czech Collection of Microorganisms (CCM, Brno, Czech Republic) and grown at 37 °C and 200 rpm in Luria–Bertani (LB) broth or on LB agar plates supplemented with 10 μg mL−1 chloramphenicol (Cm), when appropriate. E. coli DH5α (Invitrogen, Lofer, Austria) was grown in LB broth at 37 °C supplemented with 30 μg mL−1 Cm, when appropriate.
Table 3.
Bacterial strains and plasmids used in this study
| Strain or plasmid | Genotype and/or relevant characteristics | Source or reference |
|---|---|---|
| Strains | ||
| P. alvei CCM 2051T | Wild-type isolate, Kmr | Czech collection of microorganisms (CCM) |
|
P. alvei CCM 2051T wsfP::Ll.LtrB |
S-Layer glycosylation deficient mutant carrying a targetron insertion at the wsfP gene; Kmr | Ref. 31 |
| Escherichia coli DH5α | F− ϕ80dlacZΔM15 Δ (lacZYA-argF)U169 deoR recA1 endA1 hsdR17 (rK− mK−) phoA supE44 thi-1 gyrA96 relA1 λ− | Invitrogen |
| Plasmids | ||
| pEXALV | P. alvei expression vector | Ref. 31 |
| pEGFP-N1 | Expression vector for mammalian cells encoding a red-shifted variant of wild-type GFP | BD biosciences |
| pEXALV_SP_SpaA_6HIS | pEXALV carrying the his-tagged spaA gene of P. alvei CCM 2051T | This study |
| pEXALV_SP_SpaA | pEXALV carrying the spaA gene of P. alvei CCM 2051T lacking the TAA stop codon | This study |
| pEXALV_SP_SpaA_EGFP | pEXALV carrying a spaA-egfp fusion construct | This study |
4.2. Analytical and general methods
Genomic DNA of P. alvei CCM 2051T was isolated as described recently.31 Restriction and cloning enzymes were purchased from Invitrogen. The MinElute gel extraction kit (Qiagen, Vienna, Austria) was used to purify DNA fragments from agarose gels, and the MinElute reaction cleanup kit (Qiagen) was used to purify digested oligonucleotides and plasmids. Plasmid DNA from transformed cells was isolated with the Plasmid Miniprep kit (Qiagen). Agarose gel electrophoresis was performed as described elsewhere.44 Transformation of E. coli DH5α was done according to the manufacturer’s protocol (Invitrogen). Transformants were screened by in situ PCR using RedTaq ReadyMix PCR mix (Sigma–Aldrich, Vienna, Austria); recombinant clones were analyzed by restriction mapping and confirmed by sequencing (Agowa, Berlin, Germany). Transformation of P. alvei CCM 2051T was performed as described recently.31 SDS–PAGE was carried out according to a standard protocol45 using a Protean II electrophoresis apparatus (Bio-Rad, Vienna, Austria). Protein bands were visualized with Coomassie Brilliant Blue G250 staining reagent. Western blotting using a Mini Trans-Blot Cell (Bio-Rad) was performed to transfer the proteins to a polyvinylidene difluoride membrane (Bio-Rad). Anti-GFP mouse antibody (Roche, Vienna, Austria) and anti-His-tag mouse antibody (Novagen, Darmstadt, Germany) were used in combination with goat anti-mouse IgG IR Dye 800CW conjugate (Li-Cor, Lincoln, NB, USA) to detect EGFP and hexahistidine epitopes using the Li-Cor Odyssey Infrared Imaging System (Li-Cor). The integrated intensity of detected bands was determined using the Li-Cor Odyssey Application Software 3.0.21. Isolation and purification of S-layer glycoprotein essentially followed published methods.46 Qiagen’s Ni-NTA Spin Kit was used to purify hexahistidine-tagged S-layer glycoprotein under denaturing conditions. Deglycosylation of S-layer glycoprotein and amino-terminal sequencing (Edman degradation) were performed as published previously.47
4.3. PCR and DNA sequencing
PCR (My Cycler™, Bio-Rad) was performed using the Herculase® II Fusion DNA Polymerase (Stratagene, La Jolla, CA, USA). For each primer pair (Table 4), PCR conditions were optimized, and amplification products were purified using the MinElute PCR purification kit (Qiagen). Primers for PCR and DNA sequencing were purchased from Invitrogen. For sequence determination of the spaA gene including upstream and downstream regions, chromosome walking was applied as previously described.48,49
Table 4.
Oligonucleotide primers used for PCR amplification reactions
| Oligonucleotide | Sequence (5′→3′)a |
|---|---|
| proof_wSpa_for | GCIGAYGCIGCIAARACIACICARG |
| SP_SpaA_SphI_for | aatcaGCATGCAGAAAAGATTGGCCCTTCTGCTTTCCG |
| SpaA_6HIS_STOP_KpnI_rev | aatcaGGTACCttaatggtgatggtgatggtgCTTACCGGAGTATGTTCCAGGAAGG |
| SpaA_noSTOP_PstI_rev | aatcaCTGCAGCTTACCGGAGTATGTTCCAGGAAGG |
| EGFP_for_PstI | aatcaCTGCAGATGGTGAGCAAGGGCGAGGAGC |
| EGFP_rev_KpnI | aatcaGGTACCTTACTTGTACAGCTCGTCCATGCC |
Artificial restriction sites are underlined.
4.4. Sequence analysis
Nucleotide and protein sequences were analyzed using the BLASTN and BLASTP sequence homology analysis tools (National Center for Biotechnology Information, Bethesda, MD, USA). Open reading frames in the DNA sequence were identified by using the Clone Manager Professional Suite (SECentral, Cary, NC, USA) and the ORF Finder analysis tool (National Center for Biotechnology Information). For the identification of putative protein transmembrane-spanning domains and the presence and location of signal peptide cleavage sites, the TMHMM Server v. 2.0 transmembrane prediction program and the SignalP 3.0 Server (Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark) were used, respectively. The G+C content of a certain DNA sequence was determined using the GC Content and GC Skew program (Nano+Bio-Center, University of Kaiserslautern, Germany). For in silico reverse translation the Sequence Manipulation Suite was used.50 Bacterial promoters, transcriptional terminators, operons, and genes were predicted by the BProm and FindTerm modules of the FGenesB gene prediction program in Molquest software (SoftBerry, Mount Kisco, NY, USA). The presence of conserved motifs in a given protein sequence was analyzed by the Pfam protein families database,51 the SUPERFAMILY database,52 and the Conserved Domain Finder of the National Center for Biotechnology Information.53–55 Physical and chemical parameters for a given protein were calculated using the ProtParam tool.56 For pairwise alignments of certain protein sequences, the EMBOSS Pairwise Alignment Algorithms were used.57
The phylogenetic tree was calculated with the Blast Tree View Widget using the Neighbor Joining method58 and visualized using iTOL.59 Sequences with more than 0.85 difference were removed from the treeview.
4.5. Construction of the SpaA surface display constructs
The P. alvei expression vector pEXALV was used for construction of all SpaA surface display constructs. The carboxy-terminal hexahistidine tag was fused to the coding sequence of spaA by PCR using primers SP_SpaA_SphI_for and SpaA_6HIS_STOP_KpnI_rev, with genomic DNA of P. alvei CCM 2051T as template. The ~3000-bp PCR product was digested with SphI and KpnI and ligated into SphI/KpnI-linearized and dephosphorylated plasmid pEXALV. This construct was named pEXALV_SP_SpaA_6HIS. For the construction of an S-layer-EGFP fusion protein, the DNA fragment encoding the spaA gene lacking the TAA stop codon was amplified by PCR using primers SP_SpaA_SphI_for and SpaA_noSTOP_PstI_rev with genomic DNA of P. alvei CCM 2051T as template. The ~3000-bp PCR product was digested with SphI and PstI and ligated into SphI/PstI-linearized and dephosphorylated plasmid pEXALV. This construct was named pEXALV_SP_SpaA. The 742-bp egfp fragment was amplified by PCR from plasmid pEGFP-N1 using the primers EGFP_for_PstI and EGFP_rev_KpnI, digested with PstI and KpnI, and cloned in frame into PstI/KpnI-linearized and dephosphorylated plasmid pEXALV_SP_SpaA. This construct was named pEXALV_SP_SpaA_EGFP.
4.6. Analysis of cell surface display and immunofluorescence staining of SpaA-constructs
The surface accessibility of the displayed hexahistidine-tagged S-layer protein SpaA_6HIS on intact P. alvei cells was analyzed by direct immunofluorescence staining followed by fluorescence microscopy. Briefly, cells transformed with pEXALV_SP_SpaA_6HIS were harvested after expression at an OD600 ~0.6, resuspended, and washed three times in phosphate-buffered saline (PBS). After resuspension in 200 μL of PBS, 10 μL of penta-His Alexa Fluor 555 conjugate (Qiagen) was added and incubated for 2 h at room temperature on a horizontal shaker. After washing for three times, the cells were resuspended in 500 μL of PBS and analyzed by fluorescence microscopy. To directly assess the functional surface expression of the chimeric S-layer fusion protein SpaA_EGFP, P. alvei cells transformed with pEXALV_SP_SpaA_EGFP were analyzed by fluorescence microscopy. Fluorescence microscope imaging of intact P. alvei cells was carried out with a Nikon Eclipse TE2000-S inverted fluorescence microscope with a Hg vapor lamp, a Nikon digital sight DS-Qi1Mc camera, and the NIS-Elements imaging software using the TRITC (540/25 nm for excitation light, 605/55 nm for emission light) filter block for Alexa Fluor 555 and the GFP LP (480/40 nm for excitation light, long pass at 510 nm for emission light) filter block for EGFP.
Acknowledgments
We thank Andrea Scheberl and Sonja Zayni for excellent technical assistance. Financial support came from the Austrian Science Fund, project P20745-B11 (to P.M.) and projects P19047-B12 and P20605-12 (to C.S.), and the Hochschuljubiläumsstiftung der Stadt Wien, project H-02229-2007 (to K.Z.).
References
- 1.Georgiou G, Stathopoulos C, Daugherty PS, Nayak AR, Iverson BL, Curtiss R., 3rd Nat. Biotechnol. 1997;15:29–34. doi: 10.1038/nbt0197-29. [DOI] [PubMed] [Google Scholar]
- 2.Miller KD, Pefaur NB, Baird CL. Curr. Protoc. Cytom. 2008;45:1–30. doi: 10.1002/0471142956.cy0407s45. [DOI] [PubMed] [Google Scholar]
- 3.Daugherty PS. Curr. Opin. Struct. Biol. 2007;17:474–480. doi: 10.1016/j.sbi.2007.07.004. [DOI] [PubMed] [Google Scholar]
- 4.Ishige T, Honda K, Shimizu S. Curr. Opin. Chem. Biol. 2005;9:174–180. doi: 10.1016/j.cbpa.2005.02.001. [DOI] [PubMed] [Google Scholar]
- 5.Wu CH, Mulchandani A, Chen W. Trends Microbiol. 2008;16:181–188. doi: 10.1016/j.tim.2008.01.003. [DOI] [PubMed] [Google Scholar]
- 6.Saleem M, Brim H, Hussain S, Arshad M, Leigh MB, Ziaul H. Biotechnol. Adv. 2008;26:151–161. doi: 10.1016/j.biotechadv.2007.10.002. [DOI] [PubMed] [Google Scholar]
- 7.Samuelson P, Gunneriusson E, Nygren P-Å, Ståhl S. J. Biotechnol. 2002;96:129–154. doi: 10.1016/s0168-1656(02)00043-3. [DOI] [PubMed] [Google Scholar]
- 8.Lee SY, Choi JH, Xu Z. Trends Biotechnol. 2003;21:45–52. doi: 10.1016/s0167-7799(02)00006-9. [DOI] [PubMed] [Google Scholar]
- 9.Wernerus H, Ståhl S. Biotechnol. Appl. Biochem. 2004;40:209–228. doi: 10.1042/BA20040014. [DOI] [PubMed] [Google Scholar]
- 10.Desvaux M, Dumas E, Chafsey I, Hebraud M. FEMS Microbiol. Lett. 2006;256:1–15. doi: 10.1111/j.1574-6968.2006.00122.x. [DOI] [PubMed] [Google Scholar]
- 11.Gai SA, Wittrup KD. Curr. Opin. Struct. Biol. 2007;17:467–473. doi: 10.1016/j.sbi.2007.08.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Pepper LR, Cho YK, Boder ET, Shusta EV. Comb. Chem. High Throughput Screening. 2008;11:127–134. doi: 10.2174/138620708783744516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Bingle WH, Nomellini JF, Smit J. Mol. Microbiol. 1997;26:277–288. doi: 10.1046/j.1365-2958.1997.5711932.x. [DOI] [PubMed] [Google Scholar]
- 14.Bingle WH, Nomellini JF, Smit J. J. Bacteriol. 1997;179:601–611. doi: 10.1128/jb.179.3.601-611.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Mesnage S, Tosi-Couture E.; Fouet, A. Mol. Microbiol. 1999;31:927–936. doi: 10.1046/j.1365-2958.1999.01232.x. [DOI] [PubMed] [Google Scholar]
- 16.Mesnage S, Tosi-Couture E, Mock M, Fouet A. J. Appl. Microbiol. 1999;87:256–260. doi: 10.1046/j.1365-2672.1999.00880.x. [DOI] [PubMed] [Google Scholar]
- 17.Mesnage S, Weber-Levy M, Haustant M, Mock M, Fouet A. Infect. Immun. 1999;67:4847–4850. doi: 10.1128/iai.67.9.4847-4850.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Bingle WH, Nomellini JF, Smit J. J. Bacteriol. 2000;182:3298–3301. doi: 10.1128/jb.182.11.3298-3301.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Smit J. Structure. 2008;16:1151–1153. doi: 10.1016/j.str.2008.07.003. [DOI] [PubMed] [Google Scholar]
- 20.Sleytr UB, Huber C, Ilk N, Pum D, Schuster B, Egelseer EM. FEMS Microbiol. Lett. 2007;267:131–144. doi: 10.1111/j.1574-6968.2006.00573.x. [DOI] [PubMed] [Google Scholar]
- 21.Nomellini JF, Duncan G, Dorocicz IR, Smit J. Appl. Environ. Microbiol. 2007;73:3245–3253. doi: 10.1128/AEM.02900-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Engelhardt H, Peters J. J. Struct. Biol. 1998;124:276–302. doi: 10.1006/jsbi.1998.4070. [DOI] [PubMed] [Google Scholar]
- 23.May A, Pusztahelyi T, Hoffmann N, Fischer RJ, Bahl H. Arch. Microbiol. 2006;185:263–269. doi: 10.1007/s00203-006-0092-x. [DOI] [PubMed] [Google Scholar]
- 24.Mesnage S, Fontaine T, Mignot T, Delepierre M, Mock M, Fouet A. EMBO J. 2000;19:4473–4484. doi: 10.1093/emboj/19.17.4473. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Sára M. Trends Microbiol. 2001;9:47–49. doi: 10.1016/s0966-842x(00)01905-3. Discussion 49–50. [DOI] [PubMed] [Google Scholar]
- 26.Cava F, de Pedro MA, Schwarz H, Henne A, Berenguer J. Mol. Microbiol. 2004;52:677–690. doi: 10.1111/j.1365-2958.2004.04011.x. [DOI] [PubMed] [Google Scholar]
- 27.Schäffer C, Messner P. Microbiology. 2005;151:643–651. doi: 10.1099/mic.0.27749-0. [DOI] [PubMed] [Google Scholar]
- 28.Leoff C, Choudhury B, Saile E, Quinn CP, Carlson RW, Kannenberg EL. J. Biol. Chem. 2008;283:29812–29821. doi: 10.1074/jbc.M803234200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Messner P, Christian R, Neuninger C, Schulz G. J. Bacteriol. 1995;177:2188–2193. doi: 10.1128/jb.177.8.2188-2193.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Schäffer C, Müller N, Mandal PK, Christian R, Zayni S, Messner P. Glycoconjugate J. 2000;17:681–690. doi: 10.1023/a:1011062302889. [DOI] [PubMed] [Google Scholar]
- 31.Zarschler K, Janesch B, Zayni S, Schäffer C, Messner P. Appl. Environ. Microbiol. 2009;75:3077–3085. doi: 10.1128/AEM.00087-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Sára M, Moser-Thier K, Kainz U, Sleytr UB. Arch. Microbiol. 1990;153:209–214. [Google Scholar]
- 33.Altman E, Brisson J-R, Messner P, Sleytr UB. Biochem. Cell Biol. 1991;69:72–78. doi: 10.1139/o91-010. [DOI] [PubMed] [Google Scholar]
- 34.Hartmann E, Messner P, Allmeier G, König H. J. Bacteriol. 1993;175:4515–4519. doi: 10.1128/jb.175.14.4515-4519.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Sleytr UB, Beveridge TJ. Trends Microbiol. 1999;7:253–260. doi: 10.1016/s0966-842x(99)01513-9. [DOI] [PubMed] [Google Scholar]
- 36.Messner P, Schäffer C, Egelseer EM, Sleytr UB. In: Prokaryotic Cell Wall Compounds—Structure and Biochemistry. König H, Claus H, Varma A, editors. Springer; Berlin: 2010. pp. 53–109. [Google Scholar]
- 37.Paik SH, Chakicherla A, Hansen JN. J. Biol. Chem. 1998;273:23134–23142. doi: 10.1074/jbc.273.36.23134. [DOI] [PubMed] [Google Scholar]
- 38.Bhavsar AP, Truant R, Brown ED. J. Biol. Chem. 2005;280:36691–36700. doi: 10.1074/jbc.M507154200. [DOI] [PubMed] [Google Scholar]
- 39.Formstone A, Carballido-Lopez R, Noirot P, Errington J, Scheffers DJ. J. Bacteriol. 2008;190:1812–1821. doi: 10.1128/JB.01394-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Pavkov T, Egelseer EM, Tesarz M, Svergun DI, Sleytr UB, Keller W. Structure. 2008;16:1226–1237. doi: 10.1016/j.str.2008.05.012. [DOI] [PubMed] [Google Scholar]
- 41.Zarschler K, Janesch B, Pabst M, Altmann F, Messner P, Schäffer C. Glycobiology. 2010 doi: 10.1093/glycob/cwq035. doi:10.1093/glycob/cwq035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Sleytr UB, Egelseer EM, Ilk N, Pum D, Schuster B. FEBS J. 2007;274:323–334. doi: 10.1111/j.1742-4658.2006.05606.x. [DOI] [PubMed] [Google Scholar]
- 43.Schäffer C, Messner P. Biochimie. 2001;83:591–599. doi: 10.1016/s0300-9084(01)01299-8. [DOI] [PubMed] [Google Scholar]
- 44.Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY: 1989. [Google Scholar]
- 45.Laemmli UK. Nature. 1970;227:680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
- 46.Messner P, Sleytr UB. In: Bacterial Cell Surface Techniques. Hancock IC, Poxton IR, editors. John Wiley & Sons; Chichester: 1988. pp. 97–104. [Google Scholar]
- 47.Schäffer C, Wugeditsch T, Kählig H, Scheberl A, Zayni S, Messner P. J. Biol. Chem. 2002;277:6230–6239. doi: 10.1074/jbc.M108873200. [DOI] [PubMed] [Google Scholar]
- 48.Kneidinger B, Graninger M, Messner P. Biotechniques. 2001;30:248–249. doi: 10.2144/01302bm01. [DOI] [PubMed] [Google Scholar]
- 49.Pilhofer M, Bauer AP, Schrallhammer M, Richter L, Ludwig W, Schleifer KH, Petroni G. Nucleic Acids Res. 2007;35:e135. doi: 10.1093/nar/gkm836. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Stothard P. Biotechniques. 2000;28:1102–1104. doi: 10.2144/00286ir01. [DOI] [PubMed] [Google Scholar]
- 51.Finn RD, Tate J, Mistry J, Coggill PC, Sammut SJ, Hotz HR, Ceric G, Forslund K, Eddy SR, Sonnhammer EL, Bateman A. Nucleic Acids Res. 2008;36:D281–D288. doi: 10.1093/nar/gkm960. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Gough J, Karplus K, Hughey R, Chothia C. J. Mol. Biol. 2001;313:903–919. doi: 10.1006/jmbi.2001.5080. [DOI] [PubMed] [Google Scholar]
- 53.Marchler-Bauer A, Bryant SH. Nucleic Acids Res. 2004;32:W327–W331. doi: 10.1093/nar/gkh454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Marchler-Bauer A, Anderson JB, Cherukuri PF, DeWeese-Scott C, Geer LY, Gwadz M, He S, Hurwitz DI, Jackson JD, Ke Z, Lanczycki CJ, Liebert CA, Liu C, Lu F, Marchler GH, Mullokandov M, Shoemaker BA, Simonyan V, Song JS, Thiessen PA, Yamashita RA, Yin JJ, Zhang D, Bryant SH. Nucleic Acids Res. 2005;33:D192–D196. doi: 10.1093/nar/gki069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Marchler-Bauer A, Anderson JB, Derbyshire MK, DeWeese-Scott C, Gonzales NR, Gwadz M, Hao L, He S, Hurwitz DI, Jackson JD, Ke Z, Krylov D, Lanczycki CJ, Liebert CA, Liu C, Lu F, Lu S, Marchler GH, Mullokandov M, Song JS, Thanki N, Yamashita RA, Yin JJ, Zhang D, Bryant SH. Nucleic Acids Res. 2007;35:D237–D240. doi: 10.1093/nar/gkl951. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A. In: The Proteomics Protocols Handbook. Walker JM, editor. Humana Press; Totowa, NJ: 2005. pp. 571–607. [Google Scholar]
- 57.Needleman SB, Wunsch CD. J. Mol. Biol. 1970;48:443–453. doi: 10.1016/0022-2836(70)90057-4. [DOI] [PubMed] [Google Scholar]
- 58.Saitou N, Nei M. Mol. Biol. Evol. 1987;4:406–425. doi: 10.1093/oxfordjournals.molbev.a040454. [DOI] [PubMed] [Google Scholar]
- 59.Letunic I, Bork P. Bioinformatics. 2007;23:127–128. doi: 10.1093/bioinformatics/btl529. [DOI] [PubMed] [Google Scholar]





